fashion -WSS

fashion

author：hotspot 2025-08-12 08:26:06 - browse：8

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： What will save rural psychiatry services? Higher Medicaid payments

focus

WSS

House looks to weaken Medicare negotiation

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

iTeos Therapeutics debuts first data on TIGIT

Obesity now affects over 1 billion people worldwide, study finds

Kenai launches with $82 million for Parkinson’s stem cell therapy

Health insurers say they are turning to AI to cut costs, improve care

knowledge

fashion

explore

Medicare proposal to cover medical devices draws a mixed reaction

Kenai launches with $82 million for Parkinson’s stem cell therapy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA does about

Drug repurposing or repositioning? The language matters

An inside look at PIPEs, biotech's buzzy new financing tool

As demand for Covid shots wanes, Moderna seeks its next success

Scientists unlock the key to scar

Affirmative action in medical school literally saved lives

Akili, maker of video game for ADHD, to be acquired for 34 million

hotspot

Report: NIH

Do more moles mean more problems? Not so, says new study

Dark money group runs ads on China biotech bill

AI used to predict Covid

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

explore

explore

focus

knowledge